Allogeneic Human Mesenchymal Stem Cell Infusion for Frailty Patient

Inclusion Criteria: * Age of 60-85 years old at the time of screening * Those who have been confirmed frailty indication through The Frail questionnaires * Those who voluntarily decided to participate in the study and wrote the informed consent form * Those who are suitable as subjects for this study when judged by physical examination, clinical test, medical test, et cetera Exclusion Criteria: * Subject that not able to perform any of the assessments required for endpoint analysis * Those who have hypersensitivity reaction or a history of hypersensitivity to the components of the investigational product or the investigational product * Subject with Mini Mental State Examination (MMSE) score less than 24 * Abnormal laboratory result, including Hemoglobin (Hb) \<8 g/dl, Leukocyte \<3000/mm3, platelets \<80,000/mm3, International Normalized Ratio (INR) \> 1.5, aspartate transaminase and alanine transaminase \> 3 times upper limit of normal, total bilirubin \> 1.5 mg/dl, serum creatinine \> 2 mg/dL * Organ transplant recipient or already listed (or expected to be listed) for transplantation of any organ * Patient taking immunosuppressive drugs within 6 months of screening * Having serious comorbidities that may compromise the safety and compliance of the patient based on investigator judgement, including but not limited to: 1) Heart: unstable angina, myocardial infarction, class III/IV congestive heart failure, cardiac revascularization within the last six months, 2) Liver: A…